Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mircera maintenance in dialysis patients with chronic renal anaemia
NCT01156363Phase 4Completed
- Sponsor
- Roche
- Start
- Oct 2010
- Primary completion
- Jan 2013
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of methoxy polyethylene glycol-epoetin beta in anemia of chronic kidney disease (CKD-A), sponsored by Roche. Primary endpoint: Percentage of Participants Maintaining Average Hemoglobin (Hb) Concentration Within the Target Range. Started Oct 2010; status: completed.
02
Drugs
methoxy polyethylene glycol-epoetin beta
03
Conditions
anemia of chronic kidney disease (CKD-A)
Beyond the preview
Go deeper on NCT01156363.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01156363.